OptimizeRx Corporation (OPRX)
After hours:
| Previous close | 10.70 |
| Open | 10.94 |
| Bid | 10.56 x 100 |
| Ask | 10.65 x 100 |
| Day's range | 10.60 - 10.97 |
| 52-week range | 6.92 - 16.65 |
| Volume | |
| Avg. volume | 133,851 |
| Market cap | 193.113M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET
1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patie
- GlobeNewswire
OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2024. As a company that provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at cr
- GlobeNewswire
OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results
Q4 revenue of $28.4 million, increasing 44% year-over-yearQ4 gross profit increased 43% year-over-year to $17.8 million with gross margins coming in at 63% for both periodsAcquired Healthy Offers, Inc. (dba Medicx Health), a leading healthcare consumer-focused omnichannel marketing and analytics company that significantly expands our footprint with consumers and patientsMeaningfully increased our DAAP footprint: 24 DAAP deals in 2023 compared to six deals in 2022 WALTHAM, Mass., April 16, 2024 (
